Months after teaming up on RTK inhibitor Lenvima, Eisai/Merck win new FDA OK in liver cancer
Eisai’s star cancer drug Lenvima — the subject of a recent $300 million pact with Merck — just got the green light from regulators to treat a new indication in liver cancer.
The drug, whose generic name is lenvatinib, was already approved by the FDA in 2015 to treat thyroid cancer, and in 2016 it won approval for renal cell carcinoma. But the med has been lined up to take a shot at several new indications, including this latest OK in hepatocellular carcinoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.